Skip to main content

Ginkgo biloba

Scientific Name(s): Ginkgo biloba L.
Common Name(s): Ginkgo, Ginkyo, Kew tree, Maidenhair tree, Yinhsing (Japanese silver apricot)

Medically reviewed by Last updated on Dec 19, 2022.

Clinical Overview


Ginkgo has been studied extensively in diverse medical conditions. Findings from large trials have been pivotal in evaluating the efficacy of G. biloba extracts; however, there is not enough quality evidence to support the use of ginkgo for any indication. Evidence is lacking to support a protective role in cardiovascular conditions and stroke. Ginkgo's place in therapy for dementia seems limited, and a role in schizophrenia has not been established. Additionally, data do not support enhanced cognitive function resulting from G. biloba use in healthy individuals. Although interest exists in chemotherapeutic applications, safety concerns persist.


Standardized ginkgo leaf extracts have been used in clinical trials for cognitive and cardiovascular disorders at daily doses of 120 to 240 mg.


Contraindications have not been established.


Information regarding safety and efficacy in pregnancy and lactation is lacking. Ginkgo should be used with caution during pregnancy, particularly around labor due to risk of prolonged bleeding time, and should be avoided during lactation.


At recommended doses, standardized preparations of ginkgo leaf extract are unlikely to exhibit any clinically important interactions.

Adverse Reactions

Severe adverse reactions are rare; possible reactions include headache, dizziness, heart palpitations, and GI and dermatologic reactions. Ginkgo pollen can be strongly allergenic. Contact with the fleshy fruit pulp may cause allergic dermatitis similar to that caused by poison ivy.


Concerns persist regarding the safety of ginkgo leaf extract, based on studies in rodents that suggested increased mitosis and proliferation of tumor cells, as well as the large Ginkgo Evaluation of Memory (GEM) study in which the potential for an increased risk of certain cancers was noted. Consumption of the seeds may induce a toxic syndrome.

Scientific Family


The dioecious ginkgo is the world's oldest living tree species. It has been traced back more than 200 million years to fossils of the Permian geologic period and is the sole survivor of the family Ginkgoaceae. Individual trees may live as long as 1,000 years and grow to a height of approximately 38 m. Ginkgo has characteristic fan-shaped leaves. Male trees older than 20 years blossom in the spring, and adult female trees produce plum-like, yellow-brown drupe that fall in late autumn. The fleshy layer and pulp have a foul, offensive odor and can cause contact dermatitis. The edible inner seed resembles an almond and is sold in Asian markets.USDA 2018, WHO 1999


The ginkgo species almost became extinct during the last ice age that began approximately 2 million years ago. The species survived in China, where it was cultivated as a sacred tree, and it still decorates Buddhist temples throughout Asia. Ginkgo preparations have been used for medicinal purposes for more than 1,000 years. Traditional Chinese physicians used ginkgo leaves to treat asthma and chilblains. Roasted ginkgo seeds were consumed in ancient China and Japan and were considered a digestive aid and preventive agent for drunkenness. In the Western world, ginkgo has been used since the 1960s, when technology made it possible to isolate its active compounds. The flavonoids act as free radical scavengers, and the terpenes (ginkgolides) inhibit platelet-activating factor. Ginkgo is one of the most commonly prescribed medications in Europe, but it is not approved for medical use in the United States, where it is sold only as a nutritional supplement.Mohanta 2014, WHO 1999


Reviews of the chemical constituents of ginkgo have been published. Analytical methods, biological standardization, and fingerprinting of ginkgo extracts have been reported.Liu 2015, Ude 2013, van Beek 2009

The main medicinal constituents of ginkgo are found in the leaf. These include flavonoids and several terpene trilactones unique to ginkgo (ginkgolides and bilobalide). The 3 major flavonoids of ginkgo are quercetin, kaempferol, and isorhamnetin. Approximately 40 minor flavonoids have also been identified, including catechins, dehydrocatechins (proanthocyanidins), and flavones (eg, ginkgetin, amentoflavone, bilobetin, sciadopitysin). The major terpene molecules unique to ginkgo are ginkgolides A, B, C, J, and M and bilobalide. Other medicinal constituents of ginkgo include shikimic, vanillic, ascorbic, and p-coumaric acids. Other leaf components include the steroids sitosterol and stigmasterol, polyprenols, benzoic acid derivatives, carbohydrates, straight chain hydrocarbons, alcohol, ketones, and 2-hexenol. There is seasonal variation in active compound content of the leaves, with the highest amounts present in autumn.Liu 2015, Ude 2013, van Beek 2009

The seed portion of ginkgo contains carbohydrate (38%), protein (4%), and less than 2% fat. Ginkgotoxin, amino acids, cyanogenetic glycosides, and long-chain phenols, including anacaric acid, bilobol, and cardanol, are also present. Ginkgolic acid and related alkylphenols from the lipid fraction of the fruit pods have been reviewed. The foul-smelling odor of the fleshy portion of the seedcoat is caused by high concentrations of butanoic and hexanoic acids. 4-O-methylpyridoxine has been isolated from the seeds.Liu 2015, Ude 2013, USDA 2018, van Beek 2009

Uses and Pharmacology


Animal and in vitro data

A standardized extract of G. biloba leaves has been examined in several forms of cancer, and numerous mechanisms of action have been proposed based on in vitro studies.(Cao 2017, Eli 2006, Li 2002, Liu 2017, Lou 2017, Park 2017, Pretner 2006) Some animal experiments suggest that ginkgo leaf extract reduces the risk of oral cavity, stomach, and colorectal cancer.(Ahmed 2017, Chen 2005, Kim 2005, Wang 2000) The deleterious effects of electromagnetic radiation on hippocampal cells were reduced by ginkgo extract given to rats for 1 month,(Gevrek 2018) and a protective effect was reported in bleomycin-induced lung fibrosis in rats.(Iraz 2006)

Conversely, in a mouse colon cancer model, ginkgo exacerbated metastasis to the liver and decreased necrosis and apoptosis of tumor cells.(Wang 2017) This is potentially explained by observed carcinogenicity of quercetin in rodents.(Wang 2017)

Clinical data

Limited clinical studies evaluating use of ginkgo in cancer have produced equivocal findings. Smaller clinical studies have generally reported positive findings,(Bonassi 2018, Hauns 2001, Xu 2003) and one epidemiologic study claimed that ginkgolide A and B may be associated with chemoprevention of certain forms of ovarian cancer.(Ye 2007) However, in an analysis of cancer as a secondary end point in the 3,069 participants of the GEM study, no protective effect of ginkgo was observed. For site-specific cancers, there were nonsignificant trends towards an increased risk of breast (hazard ratio [HR], 2.15; 95% CI, 0.97 to 4.8; P=0.06) and colorectal (HR, 1.62; 95% CI, 0.92 to 2.87; P=0.1) cancers, and a reduced risk of prostate cancer (HR, 0.71; 95% CI, 0.43 to 1.17; P=0.18).(Biggs 2010)

Antioxidant effects of G. biloba extract were studied in Chernobyl nuclear accident recovery workers with clastogenic factors evidenced as DNA fragmentation and damage. G. biloba extract was tested on the plasma of salvage personnel; after 2 months of treatment at 120 mg per day, plasma clastogenic factors regressed or completely disappeared.(Eli 2006, Emerit 1995) An anticlastogenic effect was demonstrated for ginkgo versus placebo in patients with Graves disease who were receiving radioiodine therapy.(Dardano 2007)

Cardiovascular disease and stroke

Animal data

Animal studies report efficacy in preventing cardiovascular conditions, and researchers have attempted to explain the mechanisms by which the extract may act.(Abdel-Zaher 2017, Jiang 2017, Li 2009, Tang 2017, Wu 2008) Antiplatelet activity has been described, although evidence from controlled studies consistently indicates that ginkgo does not significantly impact hemostasis.(Bone 2008)

Clinical data

Evidence is lacking to support a protective role in cardiovascular conditions and stroke.

The GEM study (N=3,069 elderly men and women) preplanned an evaluation of cardiovascular outcomes and found no evidence that ginkgo 240 mg/day reduced total or cardiovascular mortality or cardiovascular events.(Kuller 2010) A statistically significant positive finding was obtained for ginkgo in peripheral vascular disease; however, the number of events was too small to make any generalizations.(Kuller 2010) Similarly, ginkgo did not reduce blood pressure in hypertensive or normotensive participants in the GEM study.(Brinkley 2010) A 2009 Cochrane meta-analysis of 14 clinical trials evaluating the role of ginkgo in intermittent claudication found no evidence of a clinically important benefit in patients with peripheral arterial disease; the 2013 update reinforced this conclusion.(Nicolaï 2009, Nicolai 2013) The American College of Cardiology Foundation/American Heart Association guidelines for the management of peripheral artery disease (2005/2011) state that the effectiveness of ginkgo in improving walking distance for patients with intermittent claudication is marginal and not well established (level B evidence).(Anderson 2013)

A Cochrane systematic review of studies to 2005, including 10 trials (N=792) assessing the efficacy of ginkgo, found no convincing evidence to support the use of ginkgo for recovery after stroke or for improvement in neurological deficit at the end of treatment.(Zeng 2005) In 2020, a systematic review and meta-analysis of data from 13 randomized controlled studies (N=1,466) all conducted in Asia reported significant improvement in neurological function with ginkgo compared to controls (P<0.001) in patients admitted to the hospital with acute ischemic stroke or cerebral vascular accident. However, heterogeneity was high among the 5 studies that reported on neurological function with all but 1 study administering ginkgo as an IV infusion. Activities of daily living were also improved with ginkgo (3 studies, n=535; P<0.001; high heterogeneity); only 1 study administered ginkgo orally. Additionally, adverse event rates were similar between groups and no increase was found in risk of intracranial bleeding with the use of ginkgo compared to controls (5 studies, n=547; no heterogeneity). Doses of standardized ginkgo extract ranged from 120 to 160 mg/day; however, most of the studies administered treatment as an IV infusion (for 2 to 3 weeks), whereas only 5 studies used a tablet dose form (for 1 to 6 months). Overall, the strength of evidence was very low for each outcome.(Chong 2020)

In a double-blind, randomized, placebo-controlled trial (N=102), significantly more patients in the ginkgo group achieved a 50% reduction in 4-month poststroke follow-up National Institutes of Health Stroke Scale (NIHSS) score compared with baseline than those in the placebo group (58.6% vs 18.5%, respectively; P<0.05).(Oskouei 2013) In contrast, multivariate regression analysis of the trend of NIHSS scores from admission to follow-up revealed a significant decline in scores for G. biloba when adjusted for age and gender (P<0.05).(Oskouei 2013)

CNS effects

The widespread use of G. biloba extracts in clinical trials makes data from animal studies largely redundant.

Clinical data

It remains unclear whether ginkgo has a role in reducing the incidence of dementia in elderly patients or protecting against decline in cognitive function.

In a retrospective study, outcomes were compared in 189 patients 80 years or older with Alzheimer disease who had used either donepezil or standardized G. biloba extract (EGb 761) for 12 months. No differences were noted in cognitive decline, as measured by MMSE. Rates of discontinuation because of lack of effect were similar between groups; however, more donepezil patients discontinued because of adverse effects.(Rapp 2018) Secondary analysis of data from a randomized controlled trial that enrolled 150 patients with Alzheimer's disease or mild cognitive impairment found no significant difference in 6 neuropsychological outcome measures between ginkgo biloba extract and donepezil when administered alone or in combination for 6 months. Similar improvement was seen across all 3 groups. Only Mini Mental State Examination (MMSE) at month 1 was significantly lower with donepezil alone (P=0.019); otherwise, between-group comparisons were similar at months 1, 3, and 6 for MMSE, cognition, activities of daily living, geriatric depression, neuropsychiatric inventory, and quality of life. Additionally, changes in significant discriminative brain regions were observed according to treatment group that were found to correlate to specific functional magnetic resonance imaging metrics. For example, changes in 2 specific metrics were positively correlated in the right gyrus rectus in gingko patients (P=0.03) and negatively correlated in the left superior cerebellum gyrus in donepezil patients (P=0.01).(Zheng 2021) In Alzheimer patients, a meta-analysis that included data from 6 double-blind, randomized, placebo-controlled and 1 donepezil comparator trial (N=939) reported significant improvements in cognitive function (relative risk [RR],1.983; 95% confidence interval [CI], 1.521 to 2.585; P<0.001; low heterogeneity) and global clinical assessment (odds ratio=3.119; 95% CI, 2.206 to 4.410; P<0.001; low heterogeneity) with ginkgo, but an uncertain effect on activities of daily living (no heterogeneity). All studies were of high quality and used EGb 761 for a duration of therapy that ranged from 3 to approximately 7 months at doses of 120, 160, and 240 mg/day.(Liao 2020)

Results of 2 large clinical trials have been published: the GEM study (N=3,069) and the GuidAge study (N=2,854). The GEM study found no effect of ginkgo in reducing the incidence of dementia or in preventing decline in cognitive impairment among enrolled older adult participants with normal to mild cognitive impairment.(DeKosky 2008, Snitz 2009) Similarly, in the GuidAge study, long-term use of standardized ginkgo extract had no effect on the risk of progression to Alzheimer disease compared with placebo.(Vellas 2012)

In the Impact of Cholinergic Treatment Use (ICTUS) study (N=828), 96.5% of patients received cholinesterase inhibitor therapy alone and 3.5% received ginkgo in combination with cholinesterase inhibitors. Improvements in MMSE score were observed in the combination therapy group; however, changes in the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) subscale score and the Activities of Daily Living score were not significantly different. Patients receiving combination therapy were found to have a significantly higher education level (P=0.01) and lower baseline ADAS-Cog score (P<0.01) compared to those receiving cholinesterase inhibitor therapy alone.(Canevelli 2014)

A Cochrane meta-analysis (published in 2009 and including 36 trials) found that results lacked consistent evidence of clinically important effects on dementia or cognitive impairment. Some trials included in the meta-analysis were of small sample size, and treatment duration was less than 3 months in each of the studies.(Birks 2009)

The effect of G. biloba on cognitive function in healthy individuals was examined in a systematic review and meta-analysis published in 2012, which concluded that no positive effect was evident for memory, executive function, or attention in 13 studies involving more than 2,500 participants.(Laws 2012)

In a single-blind, randomized, controlled trial that enrolled patients who suffered an acute ischemic stroke within the previous 7 days, administration of ginkgo biloba extract 150 mg 3 times daily for 6 months plus 100 mg aspirin significantly improved cognitive and executive function at days 30 (P=0.0116), 90 (P=0.0165), and 180 (P=0.0004) compared to aspirin alone. Patients receiving ginkgo demonstrated less of a decline in mean MMSE scores than controls (day 180; P=0.0110). Additionally, neurological and global function were significantly better in the ginkgo group than controls at days 12 (P=0.123) and 30 (P=0.0037). However, no significant difference was noted in the incidence of vascular events between groups at the 2-year follow-up.(Li 2017)

Multiple other systematic reviews have been published, with many including subgroup analyses.(Butler 2018, Cicero 2018) Clinical studies involving commercial industry generally report greater improvements in cognitive and neuropsychiatric measures.(Gavrilova 2014, Ihl 2011, Napryeyenko 2007, Savaskan 2018, Von Gunten 2016, Yancheva 2009)

A number of guidelines have been published on the use of ginkgo in Alzheimer disease and dementia. The European Federation of Neurological Sciences guidelines on the management of Alzheimer disease (2010) state that there is insufficient evidence to support the use of ginkgo for primary prevention of dementia, and that ginkgo should not be used in the treatment of patients with mild cognitive impairment. Additionally, the guidelines state that there is inconsistent evidence supporting the use of ginkgo in the treatment or prevention of Alzheimer disease.(Hort 2010) According to a British Association for Psychopharmacology revised (third) consensus statement (2017), until further evidence is available, ginkgo cannot be recommended for either treatment or prevention of Alzheimer disease.(O'Brien 2017)

The American Academy of Neurology (AAN) practice parameter for the management of dementia (published in 2001, reaffirmed in 2003) states that some patients with unspecified dementia may benefit from G. biloba; however, evidence-based efficacy data are lacking (practice option recommendation).(Doody 2001) The American Association for Geriatric Psychiatry position statement for patients with dementia resulting from Alzheimer disease (2006) does not recommend the general use of ginkgo for Alzheimer disease.(Lyketsos 2006) The American Psychiatric Association practice guideline for the treatment of patients with Alzheimer disease and other dementias (2007) does not recommend ginkgo for routine use in treating cognitive and functional loss due to uncertainty regarding safety and efficacy.(Rabins 2007)

Ginkgo extracts have been studied in clinical trials for conditions including schizophrenia, attention-deficit/hyperactivity disorder (ADHD), dyslexia, autism, anxiety, and migraine, with varying results.(D'Andrea 2009, Donfrancesco 2007, Lovera 2007, Niederhofer 2009, Savage 2018, Woelk 2007, Yancheva 2009)

As an antioxidant, ginkgo is of interest in schizophrenia. Meta-analyses of quality clinical trials evaluating ginkgo as add-on therapy in chronic schizophrenia have been conducted; G. biloba extract performed better than placebo in the management of total and negative symptoms.(Chen 2015, Magalhães 2016, Singh 2010) However, data from a systematic review of herbal and nutritional products for treatment of ADHD in 50 children suggested that ginkgo 80 to 120 mg/day for 6 weeks provided no benefit compared with methylphenidate.(Sarris 2011)

Guidelines have been published regarding ginkgo's use in major depressive disorder and tardive dyskinesia. AAN guidelines for the treatment of tardive syndromes, including tardive dyskinesia syndrome (2013), conclude that G. biloba extract is probably useful in treatment of tardive dyskinesia syndrome; however, data are limited to inpatients with schizophrenia.(Bhidayasiri 2013) For major depressive disorder, the Canadian Network for Mood and Anxiety Treatments clinical guidelines for the management of major depressive disorder in adults (2009) state there is insufficient evidence to provide recommendations regarding use of gingko.(Ravindran 2009)

The AAN guideline on complementary and alternative medicine in multiple sclerosis (2014) advises that ginkgo is possibly effective for reducing short-term fatigue (low-quality evidence) and is ineffective for improving cognition (high-quality evidence).(Yadav 2014)


Clinical data

A limited number of small trials evaluating use of ginkgo in diabetes have been conducted. After 3-month ingestion of G. biloba extract in one study (N=20), significant (P<0.001) increases in fasting plasma levels of insulin and C-peptide, and in insulin and C-peptide area under the curve (AUC) were observed after a 2-hour 75 g oral glucose tolerance test. No changes in glucose tolerance were observed.(Kudolo 2000) In a follow-up study of type 2 diabetes patients taking oral hypoglycemic agents, ginkgo increased pancreatic beta cell function in response to glucose loading.(Kudolo 2001) Over a 3-month period, the pharmacokinetic properties of metformin 500 mg once daily were not affected by coadministration of 120 mg of ginkgo.(Kudolo 2006) Ingestion of 120 mg/day of standardized ginkgo extract for 3 months did not produce insulin resistance in nondiabetic and prediabetic populations, nor did it exacerbate the disease in type 2 diabetic subjects.(Aziz 2018, Kudolo 2006)

Menopause/Sexual dysfunction

Clinical data

Evidence is lacking regarding the role of gingko in the management of menopausal symptoms or sexual function in women.(Reid 2014, Wheatley 2004) Clinical trials with small sample sizes have produced varying and equivocal results regarding effects of ginkgo on sexual function.(Ashton 2000, Boone 2005, Oh 2006, Ozgoli 2009, Wheatley 2004) In one study (N=99), G. biloba extract had a small but significant facilitatory effect on physiological, but not subjective, sexual arousal compared to placebo. The long-term effects of G. biloba extract on sexual function were then assessed in 68 sexually dysfunctional women randomly assigned to 8 weeks of treatment with G. biloba extract 300 mg/day, placebo, sex therapy alone, or sex therapy in combination with G. biloba extract. G. biloba extract was determined to be no more effective than placebo.(Meston 2008) Canadian Society of Obstetricians and Gynaecologists revised clinical practice guidelines on managing menopause (2014) do not recommend ginkgo for reducing menopausal symptoms, based on a lack of evidence supporting clinical benefit.(Reid 2014)


Clinical data

Small studies suggest efficacy in treating migraine; however, methodological limitations (eg, open-label design, multi-ingredient preparations tested) do not allow for extrapolation of the findings.(Allais 2013)

Mountain sickness

Clinical data

Ginkgo has been evaluated for the prevention of acute mountain sickness with equivocal results with most finding no benefit.(Chow 2005, Gertsh 2004, Leadbetter 2009, Moraga 2007, Tsai 2018) Results from a systematic review and meta-analysis of 7 studies that enrolled 451 healthy nonacclimated adults were also equivocal regarding use of ginkgo biloba extract compared to placebo for the prevention of acute mountain sickness. However, when the difference in observed risks between the 2 groups was assessed, the pooled risk difference (RD=25%; 95% CI, 6% to 45%) revealed a significant risk reduction with the use of ginkgo biloba extract (P<0.001).(Tsai 2018) A network meta-analysis of pharmacological interventions for prevention of acute mountain sickness found no significant benefit for ginkgo compared to placebo, and the addition of ginkgo to acetazolamide provided no benefit over acetazolamide alone.(Sridharan 2018)

Ophthalmologic effects

Animal data

Studies in rodents suggest that antioxidant and vascular effects of ginkgo may have a role in glaucoma(Hirooka 2004, Wimpissinger 2007) and cataractogenesis prevention.(Khedr 2018)

Clinical data

Limited clinical studies have reported positive findings with G. biloba use in patients with glaucoma.(Harris 2018, Kang 2018, Ritch 2005)


Animal data

In rats with induced osteoporosis given ginkgo for 30 days, bone mineral density was improved.(Lucinda 2017)


Animal data

Protective effects were observed in a study of rats with induced periodontitis administered G. biloba extract.(Freires 2018)

Peripheral neuropathy

The updated American Academy of Neurology practice guideline summary for oral and topical treatment of painful diabetic polyneuropathy (2021) concluded that ginkgo biloba is possibly more likely than placebo to improve pain (large effect; low). They recommend that clinicians assess patient preferences for effective oral, topical, nontraditional, and nonpharmacological interventions and offer ginkgo biloba to those who prefer nontraditional interventions (Level C).(Price 2022)

Raynaud disease

Clinical data

An early double-blind, randomized, placebo-controlled pilot study (N=19) in 2002 observed a significant reduction in number of attacks when Raynaud patients were treated with 360 mg/day of a standardized ginkgo supplement (Seredrin) for 10 weeks compared to placebo (P=0.000).(Muir 2002) In contrast, no significant reduction was seen in frequency or duration of vasospastic attacks in adults with Raynaud disease after 10 weeks of the proprietary ginkgo product EGb 761 (240 mg/day). Per-protocol data were collected from 24 predominantly female patients in this double-blind, randomized placebo-controlled trial.(Bredie 2012)


Publication of clinical trial data makes available animal studies of tinnitus less relevant, except to establish a mechanism of action.(Dogan 2018, Esen 2018)

Clinical data

A Cochrane meta-analysis of 4 clinical trials (N=1,543) conducted up to March 2012 in adults with tinnitus, either as the primary complaint or as a component of cerebral insufficiency, showed no evidence that supplemental ginkgo was effective. In patients with vascular dementia or Alzheimer disease and tinnitus, a small but statistically significant reduction in tinnitus was observed.(Hilton 2013) Similar results were reported in another systematic review and meta-analysis of 4 randomized placebo-controlled clinical trials (N=1,246). No significant benefit was found for ginkgo on the severity or intensity of tinnitus or quality of life.(Kramer 2018) A literature review reports equivocal results,(Mahmoudian-Sani 2017) and a small (N=56) clinical study found no effect of ginkgo supplementation on idiopathic sudden sensorineural hearing loss for most outcomes measured, except for speech discrimination.(Koo 2016)

In 33 adults with tinnitus and hearing loss, the effect of Ginkgo biloba extract (EGb 761) with and without a digital hearing aid was assessed in a double-blind, randomized, controlled trial. Patients were allocated to 1 of 3 groups: Ginkgo 240 mg/day, hearing aid, or ginkgo plus a hearing aid. After 90 days, all groups experienced significant improvements in quality of life scores (P<0.0001 each). The improvement with ginkgo was independent of tinnitus duration, whereas improvement with the hearing aid was correlated to shorter tinnitus duration. The improvements reported in discomfort scores among all groups were statistically significant only in those fitted with a hearing aid (P=0.0002).(Radunz 2020)

The American Association of Otolaryngology – Head and Neck Surgery clinical practice guidelines for tinnitus (2014) recommend against the use of ginkgo or other dietary supplements for treating patients with persistent tinnitus (moderate-quality aggregate evidence).(Tunkel 2014)

Other uses

Limited studies suggest potential applications in hyperuricemia,(Zhang 2017) renoprotection,(Chávez-Morales 2017, Zhang 2017) aerobic performance,(Sadowska-Krępa 2017) and vitiligo.(Parsad 2003)


Standardized ginkgo leaf extracts such as EGb 761 have been used in clinical trials for cognitive and cardiovascular disorders at daily doses of 120 to 240 mg.DeKosky 2008, Kuller 2010, Snitz 2009 Extracts are usually standardized to 24% flavones and 6% terpene lactones.DeKosky 2008, Snitz 2009 Ginkgo is commercially available in several doseforms, including teas, liquids, colas, capsules, extracts, tablets, sprays, and bars.

Pharmacokinetic testing of ginkgo doseforms, including capsules, drops, and tablets, has been conducted. When ginkgo is administered orally during fasting, bioavailability is high; food did not change the AUC quantitatively but did increase the time to maximum plasma concentration.Ude 2013, Woelkart 2010

The availability of unregulated or nonstandardized products needs to be considered when using ginkgo.Yadav 2014

Pregnancy / Lactation

Although a systematic review reports that traditional and common use has not indicated substantive risks in pregnancy or lactation, very weak scientific evidence from animal and in vitro studies shows ginkgo leaf has antiplatelet activity, and low-level evidence based on expert opinion shows ginkgo leaf may be an emmenagogue. Ginkgo should be used with caution during pregnancy, particularly around labor due to risk of prolonged bleeding time, and should be avoided during lactation.Dugoua 2006 An animal study of pregnant rats treated with ginkgo 7 to 14 mg/kg/day reported reduced fetal body weights,Pinto 2007 while another study found no evidence of embryotoxicity.Fernandes 2010


At recommended doses, standardized preparations of ginkgo leaf extract are unlikely to exhibit any clinically important interactions.(Bone 2008, Unger 2013) Caution may be required with use of raw extracts of the leaf with anticoagulants, although evidence from controlled studies consistently indicates that ginkgo does not impact hemostasis.(Bone 2008)

At higher than recommended dose levels, weak induction of cytochrome P450 (CYP-450) 2C19- and weak inhibition of CYP3A4-mediated metabolism has been observed, as well as a limited effect on drug transporters.(Unger 2013) Case reports of treatment failure implicate ginkgo, including in a 41-year-old man receiving antiretroviral therapy with efavirenz and taking a G. biloba 300 mg/day supplement(Naccarato 2012); other studies suggest no interaction with raltegravir.(Blonk 2012)

The availability of unregulated or nonstandardized products, as well as potential interactions of supplements with pharmaceutical medications, must be considered when using ginkgo.(Yadav 2014)

Agents with antiplatelet properties: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of agents with antiplatelet properties. Bleeding may occur. Consider therapy modification.(Mousa 2010, Spolarich 2007, Stanger 2012, Ulbricht 2008)

Anticoagulants: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of anticoagulants. Bleeding may occur. Consider therapy modification.(Mousa 2010, Spolarich 2007, Stanger 2012, Ulbricht 2008)

Carbamazepine: CYP3A4 inducers (weak) may decrease the serum concentration of carbamazepine. Monitor therapy.(Carbatrol August 2018, Darwish 2015, Equetro September 2016, Genton 1998, Munoz 1990, Sennoune 1992, Tegretol March 2018)

Clozapine: CYP3A4 inducers (weak) may decrease the serum concentration of clozapine. Monitor therapy.(Clozaril 2015, Jerling 1994, Joos 1998, Junghan 1993, Langbehn 2000, Miller 1991, Muller 1988, Peritogiannis 2007, Raitasuo 1994, Tiihonen 1995, Van Strater 2012)

Digoxin: G. biloba does not appear to affect serum concentration of digoxin. No known interaction.(Mauro 2003)

Efavirenz: G. biloba may decrease the serum concentration of efavirenz. Monitor therapy.(Naccarato 2012, Robertson 2008, Sustiva 2013, Wiegman 2009, Zadoyan 2012)

Fosphenytoin-phenytoin: Ginkgo biloba may decrease the serum concentration of fosphenytoin-phenytoin. No action needed.(Kupiec 2005)

Herbs (anticoagulant/antiplatelet properties): Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of other herbs (anticoagulant/antiplatelet properties). Bleeding may occur. Consider therapy modification.(Mousa 2010, Spolarich 2007, Stanger 2012, Ulbricht 2008)

Lomitapide: G. biloba may increase the serum concentration of lomitapide. Consider therapy modification.(Juxtapid July 2017, Robertson 2008, Yoshioka 2004)

Midazolam: CYP3A4 inducers (weak) may decrease the serum concentration of midazolam. No action needed.(Calvert 2014, Darwish 2008, Gorski 2004, Ou 2020, Penzak 2010, Polepally 2020, Ravicti 2019, Stage 2018, Stoch 2011, Sunvepra January 2017, Tazverik January 2020, Tpoxx July 2018, Tu 2010, Walzer 2012, Xermelo October 2020, Zelboraf May 2020, Zurth 2019)

Nimodipine: CYP3A4 inducers (weak) may decrease the serum concentration of nimodipine. Monitor therapy.(Nimodipine 2015, Tartara 1991)

Nonsteroidal anti-inflammatory agents: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of nonsteroidal anti-inflammatory drugs (NSAIDs). Bleeding may occur. Consider therapy modification.(Mousa 2010, Spolarich 2007, Stanger 2012, Ulbricht 2008)

Nonsteroidal anti-inflammatory agents (topical): Herbs (anticoagulant/antiplatelet properties) may enhance the antiplatelet effect of NSAIDs (topical). Monitor therapy.(Flector March 2019, Licart May 2020, Mousa 2010, Pennsaid May 2016, Spolarich 2007, Stanger 2012, Ulbricht 2008)

Omeprazole: G. biloba may decrease the serum concentration of omeprazole. No action needed.(Lei 2009, Yin 2004, Zadoyan 2012, Zuo 2010)

Risperidone: G. biloba may enhance the adverse/toxic effect of risperidone. No action needed.(Baytunca 2016, Ginory 2014, Lin 2007, Makesar 2007, Paklet 2013)

Salicylates: G. biloba may enhance the anticoagulant effect of salicylates. Consider therapy modification.(Bebbington 2005, Beckert 2007, Gardner 2007, Rosenblatt 1997, Wolf 2006)

Selpercatinib: CYP3A4 inducers (weak) may decrease the serum concentration of selpercatinib. Monitor therapy.(Retevmo May 2020)

Simvastatin: Ginkgo biloba may decrease the serum concentration of simvastatin. No action needed.(Dai 2013)

Tacrolimus (systemic): CYP3A4 inducers (weak) may decrease the serum concentration of tacrolimus (systemic). Monitor therapy.(Bifano 2015, Envarsus December 2018, Honda 2017, Kawaoka 2016, Smolders 2017, Ueda 2016, Ueda 2015)

Thiazide and thiazide-like diuretics: The concomitant use of thiazide and thiazide-like diuretics and G. biloba may result in hypertension. No action needed.(Shaw 1997)

Thrombolytic agents: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of thrombolytic agents. Bleeding may occur. Consider therapy modification.(Mousa 2010, Spolarich 2007, Stanger 2012, Ulbricht 2008)

Triazolam: CYP3A4 inducers (weak) may decrease the serum concentration of triazolam. No action needed.(Banzel November 2019, Villikka 1998)

Ubrogepant: CYP3A4 inducers (weak) may decrease the serum concentration of ubrogepant. Consider therapy modification.(Ubrelvy December 2019)

Valproate products: Ginkgo biloba may decrease the serum concentration of valproate products. Monitor therapy.(Granger 2001, Kupiec 2005)

Vitamin K antagonists: G. biloba may enhance the adverse/toxic effect of vitamin K antagonists. Consider therapy modification.(Engelsen 2002, Jiang 2005, Jiang 2006, Matthews 1998, Stoddard 2015)

Adverse Reactions

In large clinical trials using maximum dosages of standardized ginkgo extract 240 mg/day for durations of up to 6 years, reported adverse reactions did not differ from those in placebo groups.Birks 2009, Dekosky 2008, Snitz 2009, Weinmann 2010 A trial evaluating the safety and effectiveness of ginkgo at dosages of 240 mg/day over 22 weeks found no difference in adverse events for ginkgo compared with placebo.Napryeyenko 2009

The effect of ginkgo on platelets is unclear, but evidence from controlled studies consistently indicates that ginkgo does not impact hemostasis.Bone 2008 Case reports of increased bleeding risk exist, but clinical trials have found no effect on platelet function.Bebbington 2005, Rosenblatt 1997, Wolf 2006 Ginkgo should be used with caution in populations with bleeding risks.Page 2016

Severe adverse reactions are rare. Case reports describe headache, dizziness, and heart palpitations, as well as GI and dermatologic reactions. Injectable forms of ginkgo may cause circulatory disturbances, skin allergy, or phlebitis; parenteral ginkgo was withdrawn from the market because of the potential for severe adverse reactions.De Smet 1997

Data collected between 2004 and 2013 from 8 US centers in the Drug-induced Liver Injury Network revealed that 15.5% (130) of hepatotoxicity cases were caused by herbals and dietary supplements, whereas 85% (709) of cases were related to prescription medications. Of the 130 cases of liver injury related to supplements, 65% were from non-bodybuilding supplements and occurred most often in Hispanics/Latinos compared with non-Hispanic whites and non-Hispanic blacks. Liver transplant was also more frequent with toxicity from non-bodybuilding supplements (13%) than with conventional medications (3%) (P<0.001). Overall, the proportion of severe liver injury cases was significantly higher for supplements than for conventional medications (P=0.02). Of the 217 supplement products implicated in liver injury, 175 had identifiable ingredients, of which ginkgo biloba was among the 32 (18%) single-ingredient products.Navarro 2014

Ginkgo pollen can be strongly allergenic. Contact with the fleshy drupe pulp can cause allergic dermatitis similar to that caused by poison ivy.De Smet 1997 Case reports of seizures associated with ginkgo supplementation existGranger 2001; however, ginkgo extracts have been shown to exhibit both anti- and proconvulsant activity in animal experiments.Jahanshahi 2012, Lee 2012


Data have been reported regarding the carcinogenic potential of G. biloba extract, with increased mitosis and cell proliferation observed in some,Wang 2017 but not all, rodent studies.Fernandes 2010, Grollino 2017

Limited clinical studies have also produced equivocal findings. One study (N=47) reported no increase in liver injury markers or genomic measures (micronucleus frequency, comet assay, c-myc, p53, and ctnnb1 expression profile in lymphocytes).Bonassi 2018 In an analysis of cancer as a secondary end point in the 3,069 participants of the GEM study, no protective effect of ginkgo was observed. For site-specific cancers, there were nonsignificant trends towards an increased risk of breast (HR, 2.15; 95% CI, 0.97 to 4.8; P=0.06) and colorectal (HR, 1.62; 95% CI, 0.92 to 2.87; P=0.1) cancers, and a reduced risk of prostate cancer (HR, 0.71; 95% CI, 0.43 to 1.17; P=0.18).Biggs 2010

Ginkgo seeds have been reported to induce a toxic syndrome ("Gin-nan" food poisoning). Consumption of approximately 50 ginkgo seeds has produced convulsions in a 21-month-old child, and consumption of 70 to 80 seeds induced tonic-clonic seizures and loss of consciousness in a 36-year-old woman.Benjamin 2001, Hasegawa 2006, Miwa 2001 In a similar case, a 64-year-old woman with a 40-year history of daily alcohol intake and signs of fatty liver presented with generalized tonic-clonic seizures within 9.5 hours of consuming 50 roasted ginkgo seeds. Ginkgo biloba intoxication was confirmed by a methylpyridoxine level in excess of 3,000 nM, which was normalized within an hour of IV pyridoxal phosphate replacement. She was discharged after 3 days of hospitalization.Azuma 2020 Between 1930 and 1960, 70 reports of poisoning related to ginkgo ingestion revealed a 27% mortality rate, with infants being the most vulnerable. Ginkgotoxin (4-O-methylpyridoxine), found only in the seeds, was considered responsible for this toxicity.De Smet 1997, Newall 1996



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

Frequently asked questions

Abdel-Zaher AO, Farghaly HSM, El-Refaiy AEM, Abd-Eldayem AM. Protective effect of the standardized extract of Ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms. Biomed Pharmacother. 2017;95:944-955.28915536
Ahmed HH, El-Abhar HS, Hassanin EAK, Abdelkader NF, Shalaby MB. Ginkgo biloba L. leaf extract offers multiple mechanisms in bridling N-methylnitrosourea - mediated experimental colorectal cancer. Biomed Pharmacother. 2017;95:387-393.28858737
Allais G, D'Andrea G, Maggio M, Benedetto C. The efficacy of ginkgolide B in the acute treatment of migraine aura: an open preliminary trial. Neurol Sci. 2013;34(suppl 1):S161-S163.23695070
Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(13):1425-1243.23457117
Ashton AK, Ahrens K, Gupta S, Masand PS. Antidepressant-induced sexual dysfunction and Ginkgo Biloba. Am J Psychiatry. 2000;157(5):836-837.10784488
Aziz TA, Hussain SA, Mahwi TO, Ahmed ZA, Rahman HS, Rasedee A. The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial. Drug Des Devel Ther. 2018;12:735-742.29670330
Azuma F, Nokura K, Kako T, Kobayashi D, Yoshimura T, Wada K. An adult case of generalized convulsions caused by the ingestion of Ginkgo biloba seeds with alcohol. Intern Med. 2020;59(12):1555-1558.32132337
Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; November 2019.
Baytunca MB, Kose S, Ozbaran B, Erermis S. Risperidone, quetiapine and chlorpromazine may have induced priapism in an adolescent. Pediatr Int. 2016;58(1):61-63.26542690
Bebbington A, Kulkarni R, Roberts P. Ginkgo biloba: persistent bleeding after total hip arthroplasty caused by herbal self-medication. J Arthroplasty. 2005;20(1):125-126.15660071
Beckert BW, Concannon MJ, Henry SL, et al. The effect of herbal medicines on platelet function: An in vivo experiment and review of the literature. Plast Reconstr Surg. 2007;120(7):2044-2050.18090773
Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage-can Ginkgo biloba be implicated? Postgrad Med J. 2001;77(904):112-113.11161079
Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2013;81(22):1968]. Neurology. 2013;81(5):463-469.23897874
Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015;35(5):281-289.25896946
Biggs ML, Sorkin BC, Nahin RL, Kuller LH, Fitzpatrick AL. Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study. Pharmacoepidemiol Drug Saf. 2010;19(7):694-698.20582906
Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(1):CD003120.19160216
Blonk M, Colbers A, Poirters A, Schouwenberg B, Burger D. Effect of Ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers. Antimicrob Agents Chemother. 2012;56(10):5070-5075.22802250
Bonassi S, Prinzi G, Lamonaca P, et al. Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN 5933/Ginkgoselect Plus) in elderly: a randomised placebo-controlled clinical trial [GiBiEx]. BMC Complement Altern Med. 2018;18(1):22.29357859
Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res. 2008;52(7):764-771.18214851
Boone SA, Shields KM. Dietary supplements for female sexual dysfunction. Am J Health Syst Pharm. 2005;62(6):574-580.15757877
Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol. 2012;59(3):215-221.22030896
Brinkley TE, Lovato JF, Arnold AM, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens. 2010;23(5):528-533.20168306
Butler M, Nelson VA, Davila H, et al. Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018;168(1):52-62.2925590910.7326/M17-1530
Calvert H, Twelves C, Ranson M, et al. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anticancer Drugs. 2014;25(7):832-840.24637575
Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group. Effects of Ginkgo biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study. Phytomedicine. 2014;21(6):888-892.24548724
Cao C, Han D, Su Y, Ge Y, Chen H, Xu A. Ginkgo biloba exocarp extracts induces autophagy in Lewis lung cancer cells involving AMPK / mTOR / p70S6k signalling pathway. Biomed Pharmacother. 2017;93:1128-1135.2873852110.1016/j.biopha.2017.07.036
Carbatrol (carbamazepine) extended-release capsules [prescribing information]. Lexington, MA: Shire US Inc.; August 2018.
Chávez-Morales RM, Jaramillo-Juárez F, Rodríguez-Vázquez ML, Martínez-Saldaña MC, Del Río FAP, Garfias-López JA. The Ginkgo biloba extract (GbE) protects the kidney from damage produced by a single and low dose of carbon tetrachloride in adult male rats. Exp Toxicol Pathol. 2017;69(7):430-434.2841614510.1016/j.etp.2017.04.003
Chen SH, Liang YC, Chao JC, et al. Protective effects of Ginkgo biloba extract on the ethanol-induced gastric ulcer in rats. World J Gastroenterol. 2005;11(24):3746-3750.15968732
Chen X, Hong Y, Zheng P. Efficacy and safety of extract of Ginkgo biloba as an adjunct therapy in chronic schizophrenia: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis. Psychiatry Res. 2015;228(1):121-127.25980333
Chong PZ, Ng HY, Tai JT, Lee SWH. Efficacy and safety of Ginkgo biloba in patients with acute ischemic stroke: A systematic review and meta-analysis. Am J Chin Med. 2020;48(3):513-534.32349519
Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness. Arch Intern Med. 2005;165:296-301.15710792
Cicero AFG, Fogacci F, Banach M. Botanicals and phytochemicals active on cognitive decline: The clinical evidence [published online ahead of print December 28, 2017]. Pharmacol Res. 2018;130:204-212.2928957610.1016/j.phrs.2017.12.029
Clozaril (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2015.
Dai L-L, Fan L, Wu H-Z, et al. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects. Xenobiotica. 2013;43(10):862-867.23451885
D'Andrea G, Bussone G, Allais G, et al. Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. Neurol Sci. 2009;30(suppl 1):S121-S124.19415441
Dardano A, Ballardin M, Ferdeghini M, et al. Anticlastogenic effect of Ginkgo biloba extract in Graves' disease patients receiving radioiodine therapy. J Clin Endocrinol Metab. 2007;92(11):4286-4289.17711926
Darwish M, Bond M, Yang R, Hellriegel ET, Robertson Jr P. Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. Clin Ther. 2015;37(2):325-327.25438721
Darwish M, Kirby M, Robertson Jr P, Hellriegel ET. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74.18076219
De Smet PA, ed. Adverse Effects of Herbal Drugs. New York, NY: Springer-Verlag; 1997:51-66.
DeKosky ST, Williamson JD, Fitzpatrick AL, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial [published correction appears in JAMA. 2008;300(23):2730]. JAMA. 2008;300(19):2253-2262.19017911
Dogan R, Sjostrand AP, Yenıgun A, Karatas E, Kocyigit A, Ozturan O. Influence of Ginkgo biloba extract (EGb 761) on expression of IL-1 Beta, IL-6, TNF-alfa, HSP-70, HSF-1 and COX-2 after noise exposure in the rat cochlea. Auris Nasus Larynx. 2018;45(4):680-685.2904207110.1016/j.anl.2017.09.015
Donfrancesco R, Ferrante L. Ginkgo biloba in dyslexia: a pilot study. Phytomedicine. 2007;14(6):367-370.17517502
Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1154-1166.11342679
Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of ginkgo (Ginkgo biloba) during pregnancy and lactation. Can J Clin Pharmacol. 2006;13(3):e277-e284.17085776
Eli R, Fasciano JA. An adjunctive preventive treatment for cancer: ultraviolet light and Ginkgo biloba, together with other antioxidants, are a safe and powerful, but largely ignored, treatment option for the prevention of cancer. Med Hypotheses. 2006;66(6):1152-1156.16483725
Emerit I, Oganesian N, Sarkisian T, et al. Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Radiat Res. 1995;144(2):198-205.7480646
Engelsen J, Nielsen JD and Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost. 2002;87(6):1075-1076.12083489
Envarsus XR (tacrolimus) [prescribing information]. Cary, North Carolina: Veloxis Pharmaceuticals, Inc.; December 2018.
Equetro (carbamazepine) extended-release capsules [prescribing information]. Parsippany, NJ: Validus Pharmaceuticals LLC; September 2016.
Esen E, Özdoğan F, Gürgen SG, et al. Ginkgo biloba and lycopene are effective on cisplatin induced ototoxicity? J Int Adv Otol. 2018;14(1):22-26.2863955510.5152/iao.2017.3137
Fernandes ES, Pinto RM, de Paula Reis JE, de Oliveira Guerra M, Peters VM. Effects of Ginkgo biloba extract on the embryo-fetal development in Wistar rats. Birth Defects Res B Dev Reprod Toxicol. 2010;89(2):133-138.20437472
Flector (diclofenac epolamine) topical system [prescribing information]. New York, NY: Pfizer Inc.; March 2019.
Folium Ginkgo. In: WHO Monographs on Selected Medicinal Plants. Vol 1. Geneva, Switzerland: World Health Organization; 1999. Accessed June 26, 2018.
Freires IA, Santaella GM, de Cássia Orlandi Sardi J, Rosalen PL. The alveolar bone protective effects of natural products: A systematic review. Arch Oral Biol. 2018;87:196-203.2930677710.1016/j.archoralbio.2017.12.019
Gardner CD, Zehnder JL, Rigby AJ, et al. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: A randomized clinical trial. Blood Coagul Fibrinolysis. 2007;18(8):787-793.17982321
Gavrilova SI, Preuss UW, Wong JW, Hoerr R, Kaschel R, Bachinskaya N; GIMCIPlus Study Group. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry. 2014;29(10):1087-1095.24633934
Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia. 1998;39(10):1115-1118.9776334
Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328(7443):79715070635
Gevrek F. Histopathological, immunohistochemical, and stereological analysis of the effect of Ginkgo biloba (Egb761) on the hippocampus of rats exposed to long-term cellphone radiation. Histol Histopathol. 2018;33(5):463-473.2912003110.14670/HH-11-943
Ginkgo biloba L. USDA, NRCS. 2018. The PLANTS Database (, February 2018). National Plant Data Team, Greensboro, NC 27401-4901 USA. Accessed February 2018.
Ginory A, Nguyen M. A case of priapism with risperidone. Case Rep Psychiatry. 2014;2014:241573.25379316
Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89-100.14749695
Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing. 2001;30(6):523-525.11742783
Grollino MG, Raschellà G, Cordelli E, et al. Cytotoxicity, genotoxicity and gene expression changes elicited by exposure of human hepatic cells to Ginkgo biloba leaf extract. Food Chem Toxicol. 2017;109(pt 1):486-496.2894338710.1016/j.fct.2017.09.042
Harris A, Gross J, Moore N, et al. The effects of antioxidants on ocular blood flow in patients with glaucoma. Acta Ophthalmol. 2018;96(2):e237-e241.2877200510.1111/aos.13530
Hasegawa S, Oda Y, Ichiyama T, Hori Y, Furukawa S. Ginkgo nut intoxication in a 2-year-old male. Pediatr Neurol. 2006;35(4):275-276.16996402
Hauns B, Häring B, Köhler S, Mross K, Unger C. Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. Phytother Res. 2001;15(1):34-38.11180520
Hilton MP, Zimmermann EF, Hunt WT. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. 2013;(3):CD003852.23543524
Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res. 2004;28(3):153-157.14977516
Honda M, Sugawara Y, Watanabe T, et al. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatol Res. 2017;47(11):1147-1154.28002876
Hort J, O'Brien JT, Gainotti G, et al; EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10):1236-1248.20831773
Ihl R, Bachinskaya N, Korczyn AD, et al; GOTADAY Study Group. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26(11):1186-1194.21140383
Iraz M, Erdogan H, Kotuk M, et al. Ginkgo biloba inhibits bleomycin-induced lung fibrosis in rats. Pharmacol Res. 2006;53(3):310-316.16459098
Jahanshahi M, Nikmahzar E, Yadollahi N, Ramazani K. Protective effects of Ginkgo biloba extract (EGB 761) on astrocytes of rat hippocampus after exposure with scopolamine. Anat Cell Biol. 2012;45(2):92-96.22822463
Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16(4):368-374.7974626
Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines of warfarin response in healthy subjects: A population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol. 2006;46(11):1370-1378.17050802
Jiang H, Qu P. Effects of Ginkgo biloba leaf extract on local renin-angiotensin system through TLR4/NF-κB pathway in cardiac myocyte. Exp Ther Med. 2017;14(6):5857-5862.2928513310.3892/etm.2017.5313
Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2005;59(4):425-432.15801937
Joos AA, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. J Clin Psychopharmacol. 1998;18(1):83-85.9472849
Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry. 1993;26(6):262.8127933
Juxtapid (lomitapide) [prescribing information]. Cambridge, MA: Aegerion Pharmaceuticals, Inc.; July 2017.
Kang JM, Lin S. Ginkgo biloba and its potential role in glaucoma. Curr Opin Ophthalmol. 2018;29(2):116-120.2920665310.1097/ICU.0000000000000459
Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: case report. Hepatol Res. 2016;46(7):707-712.26439054
Khedr MH, Shafaa MW, Abdel-Ghaffar A, Saleh A. Radioprotective efficacy of Ginkgo biloba and Angelica archangelica extract against technetium-99m-sestamibi induced oxidative stress and lens injury in rats. Int J Radiat Biol. 2018;94(1):37-44.29157082
Kim KS, Rhee KH, Yoon JH, Lee JG, Lee JH, Yoo JB. Ginkgo biloba extract (EGb 761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral Oncol. 2005;41(4):383-389.15792610
Koo JW, Chang, MY, Yun SC, et al. The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trial. Eur Arch Otorhinolaryngol. 2016;273(9):2433-2441.26559533
Kramer F, Ortigoza Á. Ginkgo biloba for the treatment of tinnitus [published correction appears in Medwave. 2018 ;18(7):e7337]. Ginkgo biloba para el tratamiento del tinnitus [published correction appears in Medwave. 2018;18(7):e7337]. Medwave. 2018;18(6):e7295.30339143
Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol. 2000;40(6):647-654.10868316
Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol. 2001;41(6):600-611.11402628
Kudolo GB, Wang W, Elrod R, Barrientos J, Haase A, Blodgett J. Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects—a randomized double-blind placebo-controlled crossover study. Clin Nutr. 2006;25(1):123-134.16293352
Kudolo GB, Wang W, Javors M, Blodgett J. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects—a double blind placebo-controlled, crossover study. Clin Nutr. 2006;25(4):606-616.16698134
Kuller LH, Ives DG, Fitzpatrick AL, et al; Ginkgo Evaluation of Memory Study Investigators. Does Ginkgo biloba reduce the risk of cardiovascular events? Circ Cardiovasc Qual Outcomes. 2010;3(1):41-47.20123670
Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005;29(7):755-758.16419414
Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. Pharmacopsychiatry. 2000;33(5):196.11071023
Laws KR, Sweetnam H, Kondel TK. Is Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis. Hum Psychopharmacol. 2012;27(6):527-533.23001963
Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PH. Ginkgo biloba does—and does not—prevent acute mountain sickness. Wilderness Environ Med. 2009;20(1):66-71.19364166
Lee GH, Sung SY, Chang WN, et al. Zebrafish larvae exposed to ginkgotoxin exhibit seizure-like behavior that is relieved by pyridoxal-5′-phosphate, GABA and anti-epileptic drugs. Dis Model Mech. 2012;5(6):785-795.22736461
Lei HP, Wang G, Wang LS, et al. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother. 2009;43(4):726-731.19299322
Li S, Zhang X, Fang Q, et al. Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial [published correction appears in Stroke Vasc Neurol. 2018;3(3):189]. Stroke Vasc Neurol. 2017;2(4):189-197. doi:10.1136/svn-2017-00010429507779
Li W, Pretner E, Shen L, Drieu K, Papadopoulos V. Common gene targets of Ginkgo biloba extract (EGb 761) in human tumor cells: relation to cell growth. Cell Mol Biol (Noisy-le-grand). 2002;48(6):655-662.12396076
Li XS, Zheng WY, Lou SX, Lu XW, Ye SH. Effect of Ginkgo leaf extract on vascular endothelial function in patients with early stage diabetic nephropathy. Chin J Integr Med. 2009;15(1):26-29.19271166
Liao Z, Cheng L, Li X, Zhang M, Wang S, Huo R. Meta-analysis of Ginkgo biloba preparation for the treatment of Alzheimer's disease. Clin Neuropharmacol. 2020;43(4):93-99.32658034
Licart (diclofenac epolamine) topical system [prescribing information]. Parsippany, NJ: IBSA Pharma Inc.; May 2020.
Lin Y-Y, Chu S-J, Tsai S-H. Association between priapism and concurrent use of risperidone and ginkgo biloba. Mayo Clin Proc. 2007;82(10):1289-1290.17908535
Liu XG, Wu SQ, Li P, Yang H. Advancement in the chemical analysis and quality control of flavonoid in Ginkgo biloba. J Pharm Biomed Anal. 2015;113:212-225.25812435
Liu T, Zhang J, Chai Z, Wang G, Cui N, Zhou B. Ginkgo biloba extract EGb 761-induced upregulation of LincRNA-p21 inhibits colorectal cancer metastasis by associating with EZH2. Oncotarget. 2017;8(53):91614-91627.29207671
Lou JS, Bi WC, Chan GKL, et al. Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer. Oncotarget. 2017;8(54):93131-93148.29190983
Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler. 2007;13(3):376-385.17439907
Lucinda LMF, Aarestrup BJV, Reboredo MM, et al. Evaluation of the anti-osteoporotic effect of Ginkgo biloba L. in Wistar rats with glucocorticoid-induced-osteoporosis by bone densitometry using dual-energy x-ray absorptiometry (DEXA) and mechanical testing. An Acad Bras Cienc. 2017;89(4):2833-2841.29044313
Lyketsos CG, Colenda CC, Beck C, et al; Task Force of American Association for Geriatric Psychiatry. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease [published correction appears in Am J Geriatr Psychiatry. 2006;14(9):808]. Am J Geriatr Psychiatry. 2006;14(7):561-572.16816009
Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:CD008919.2684892610.1002/14651858.CD008919.pub2
Mahmoudian-Sani MR, Hashemzadeh-Chaleshtori M, Asadi-Samani M, Yang Q. Ginkgo biloba in the treatment of tinnitus: An updated literature review. Int Tinnitus J. 2017;21(1):58-62.28723603
Makesar D, Thome J. Risperidone-induced priapism. World J Biol Psychiatry. 2007;8(1):45-47.17366350
Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998;50(6):1933-1934.9633781
Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Therapeutics. 2003;10(4):247-251.12845387
Meston CM, Rellini AH, Telch MJ. Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women. Arch Sex Behav. 2008;37(4):530-547.18274887
Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry. 1991;52(1):23-25.1988414
Miwa H, Iijima M, Tanaka S, Mizuno Y. Generalized convulsions after consuming a large amount of gingko nuts. Epilepsia. 2001;42(2):280-281.11240603
Mohanta TK, Tamboli Y, Zubaidha PK. Phytochemical and medicinal importance of Ginkgo biloba L. Nat Prod Res. 2014;28(10):746-752.24499319
Moraga FA, Flores A, Serra J, Esnaola C, Barriento C. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile [published correction appears in Wilderness Environ Med. 2008;19(1):51]. Wilderness Environ Med. 2007;18(4):251-257.18076292
Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol. 2010;663:229-240.20617421
Muir AH, Robb R, McLaren M, Daly F, Belch JJ. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial. Vasc Med. 2002;7(4):265-267.12710841
Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet. 1988;2(8626-8627):1500.2904624
Munoz JJ, De Salamanca RE, Diaz-Obregon C, Timoneda FL. The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites. Br J Clin Pharmacol. 1990;29(6):763-765.2378792
Naccarato M, Yoong D, Gough K. A potential drug-herbal interaction between Ginkgo biloba and efavirenz. J Int Assoc Physicians AIDS Care (Chic). 2012;11(2):98-100.22323244
Napryeyenko O, Borzenko I; GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57(1):4-11.17341003
Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. J Neurol Sci. 2009;283(1-2):224-229.19286192
Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399-1408.25043597
Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996:138-140.
Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Teijink JA. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2009;(2):CD006888.19370657
Nicolai SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2013;(6):CD006888.23744597
Niederhofer H. First preliminary results of an observation of Ginkgo Biloba treating patients with autistic disorder. Phytother Res. 2009;23(11):1645-1646.19274699
Nimodipine [prescribing information]. Montvale, NJ: Ascend Laboratories LLC; April 2015.
O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147-168.28103749
Oh SM, Chung KH. Antiestrogenic activities of Ginkgo biloba extracts. J Steroid Biochem Mol Biol. 2006;100(4-5):167-176.16842996
Oskouei DS, Rikhtegar R, Hashemilar M, et al. The effect of Ginkgo biloba on functional outcome of paitents with acute ischemic stroke: a double-blind, placebo-controlled, randomized clinical trial. J Stroke Cerebrovasc Dis. 2013;22(8):e557-e563.23871729
Ou YC, Tang Z, Novotny W, et al. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. Br J Clin Pharmacol. Published online December 18, 2020. doi:10.1111/bcp.1470733336408
Ozgoli G, Selselei EA, Mojab F, Majd HA. A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome. J Altern Complement Med. 2009;15(8):845-851.19678774
Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69.27400984
Paklet L, Abe AM, Olajide D. Priapism associated with risperidone: a case report, literature review and review of the South London and Maudsley hospital patients' database. Ther Adv Psychopharmacol. 2013;3(1):3-13.23983987
Park Y, Woo SH, Seo SK, et al. Ginkgetin induces cell death in breast cancer cells via downregulation of the estrogen receptor. Oncol Lett. 2017;14(4):5027-5033.29085516
Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003;28(3):285-287.12780716
Pennsaid (diclofenac sodium) topical solution 2% [prescribing information]. Lake Forest, IL: Horizon Pharma USA Inc.; May 2016.
Penzak SR, Robertson SM, Hunt JD, et al. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy. 2010;30(8):797-805.20653355
Peritogiannis V, Pappas D, Antoniou K, Hyphantis T, Mavreas V. Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. Gen Hosp Psychiatry. 2007;29(3):281-282.17484952
Pinto RM, Fernandes ES, Reis JE, Peters VM, Guerra Mde O. Intra-uterine growth retardation after prenatal administration of Ginkgo biloba to rats. Reprod Toxicol. 2007;23(4):480-485.17287108
Polepally AR, Ng JK, Salem AH, et al. Assessment of clinical drug-drug interactions of elagolix, a gonadotropin-releasing hormone receptor antagonist. J Clin Pharmacol. 2020;60(12):1606-1616.33045114
Pretner E, Amri H, Li W, et al. Cancer-related overexpression of the peripheral-type benzodiazepine receptor and cytostatic anticancer effects of Ginkgo biloba extract (EGb 761). Anticancer Res. 2006;26(1A):9-22.16475673
Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: Practice guideline update summary: Report of the AAN guideline subcommittee. Neurology. 2022;98(1):31-43. doi:10.1212/WNL.000000000001303834965987
Rabins PV, Blacker D, Rovner BW, et al; APA Work Group on Alzheimer's Disease and other Dementias; Steering Committee on Practice Guidelines. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12)(suppl):5-56.18340692
Radunz CL, Okuyama CE, Branco-Barreiro FCA, Pereira RMS, Diniz SN. Clinical randomized trial study of hearing aids effectiveness in association with Ginkgo biloba extract (EGb 761) on tinnitus improvement. Braz J Otorhinolaryngol. 2020;86(6):734-742.31300303
Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. Psychopharmacology (Berl). 1994;116(1):115-116.7862923
Rapp M, Burkart M, Kohlmann T, Bohlken J. Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer's dementia in very old age: A retrospective observational study. Int J Clin Pharmacol Ther. 2018;56(3):130-133.29319499
Ravicti (glycerol phenylbutyrate) [prescribing information]. Lake Forest, IL: Horizon Pharma USA Inc; October 2019.
Ravindran AV, Lam RW, Filteau MJ, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord. 2009;117(suppl 1):S54-S64.19666194
Reid R, Abramson BL, Blake J, et al; Menopause and Osteoporosis Working Group. Managing Menopause. J Obstet Gynaecol Can. 2014;36(9):830-833.25222364
Retevmo (selpercatinib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; May 2020.
Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am. 2005;18(4):597-609.16314222
Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam, and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin. 2008;24(2):591-599.18205997
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med. 1997;336(15):1108.9091822
Sadowska-Krępa E, Kłapcińska B, Pokora I, Domaszewski P, Kempa K, Podgórski T. Effects of Six-Week Ginkgo biloba supplementation on aerobic performance, blood pro/antioxidant balance, and serum brain-derived neurotrophic factor in physically active men. Nutrients. 2017;9(8).28933745
Sarris J, Kean J, Schweitzer I, Lake J. Complementary medicines (herbal and nutritional products) in the treatment of attention deficit hyperactivity disorder (ADHD): a systematic review of the evidence. Complement Ther Med. 2011;19(4):216-227.21827936
Savage K, Firth J, Stough C, Sarris J. GABA-modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence. Phytother Res. 2018;32(1):3-18.29168225
Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S. Treatment effects of Ginkgo biloba extract EGb 761 on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. Int Psychogeriatr. 2018;30(3):285-293.2893144410.1017/S1041610217001892
Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit. 1992;14(4):269-274.1519299
Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Saf. 1997;17(5):342-356.9391777
Singh V, Singh SP, Chan K. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia. Int J Neuropsychopharmacol. 2010;13(2):257-271.19775502
Smolders EJ, Pape S, de Kanter CT, van den Berg AP, Drenth JP, Burger DM. Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? Int J Antimicrob Agents. 2017;49(3):379-382.28185946
Snitz BE, O'Meara ES, Carlson MC, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009;302(24):2663-2670.20040554
Spolarich AE, Andrews L. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J Dent Hyg. 2007;81(3):67.17908423
Sridharan K, Sivaramakrishnan G. Pharmacological interventions for preventing acute mountain sickness: a network meta-analysis and trial sequential analysis of randomized clinical trials. Ann Med. 2018;50(2):147-155.29166795
Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9, and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519.29105855
Stanger MJ, Thompson LA, Young AJ, et al. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012;70(2):107-117.22300597
Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol. 2011;67(6):1313-1321.20734049
Stoddard GJ, Archer M, Shane-McWhorter L, Bray BE, Redd DF, Proulx J, Zeng-Treitler Q. Ginkgo and warfarin interaction in a large veterans administration population. AMIA Annu Symp Proc. 2015;2015:1174-1183.26958257
Sunvepra (asunaprevir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; January 2017.
Sustiva (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2013.
Tang Y, Zhou G, Yao L, et al. Protective effect of Ginkgo biloba leaves extract, EGb761, on myocardium injury in ischemia reperfusion rats via regulation of TLR-4/NF-κB signaling pathway. Oncotarget. 2017;8(49):86671-86680.29156826
Tartara A, Galimberti CA, Manni R, et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol. 1991;32(3):335-340.1777370
Tazverik (tazemetostat) [prescribing information]. Cambridge, MA: Epizyme Inc; January 2020.
Tegretol (carbamazepine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2018.
Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995;28(1):26-28.7746842
Tpoxx (tecovirimat) [prescribing information]. Winchester, KY: Catalent Pharma Solutions; July 2018.
Tsai TY, Wang SH, Lee YK, Su YC. Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2018;8(8):e022005.30121603
Tu JH, He YJ, Chen Y, et al. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010;66(8):805-810.20393696
Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. Otolaryngol Head Neck Surg. 2014;151(2)(suppl):S1-S40.25273878
Ubrelvy (ubrogepant) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2019.
Ude C, Schubert-Zsilavecz M, Wurglics M. Ginkgo biloba extracts: a review of the pharmacokinetics of the active ingredients. Clin Pharmacokinet. 2013;52(9):727-749.23703577
Ueda Y, Uemoto S. Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. Transpl Int. 2016;29(1):119-121.26270021
Ueda Y, Kaido T, Hatano E, Ohtsuru S, Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatol Res. 2015;45(13):1360-1362.25704315
Ulbricht C, Chao W, Costa D, et al. Clinical evidence of herb-drug interactions: A systematic review by the Natural Standard Research Collaboration. Curr Drug Metab. 2008;9(10):1063-120.19075623
Unger M. Pharmacokinetic drug interactions involving Ginkgo biloba. Drug Metab Rev. 2013;45(3):353-385.23865865
van Beek TA, Montoro P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J Chromatogr A. 2009;1216(11):2002-2032.19195661
Van Strater AC, Bogers JP. Interaction of St John's wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol. 2012;27(2):121-124.22113252
Vellas B, Coley N, Ousset PJ, et al; GuidAge Study Group. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11(10):851-859.22959217
Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol. 1998;83(3):135-138.9783333
Von Gunten A, Schlaefke S, Überla K. Efficacy of Ginkgo biloba extract EGb 761 in dementia with behavioural and psychological symptoms: a systematic review. World J Biol Psychiatry. 2016;17(8):622-633.26223956
Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy. 2012;32(4):340-353.22422635
Wang Q, Zhao WZ, Ma CG. Protective effects of Ginkgo biloba extract on gastric mucosa. Acta Pharmacol Sin. 2000;21(12):1153-1156.11603292
Wang H, Wu X, Lezmi S, et al. Extract of Ginkgo biloba exacerbates liver metastasis in a mouse colon cancer Xenograft model. BMC Complement Altern Med. 2017;17(1):516.29197355
Wiegman DJ, Brinkman K, Franssen EJ. Interaction of Ginkgo biloba with efavirenz. AIDS. 2009;23(9):1184-1185.19451798
Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010;10:14.20236541
Wheatley D. Triple-blind, placebo-controlled trial of Ginkgo biloba in sexual dysfunction due to antidepressant drugs. Hum Psychopharmacol. 2004;19(8):545-548.15378664
Wimpissinger B, Berisha F, Garhoefer G, Polak K, Schmetterer L. Influence of Ginkgo biloba on ocular blood flow. Acta Ophthalmol Scand. 2007;85(4):445-449.17324220
Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41(6):472-480.16808927
Woelkart K, Feizlmayr E, Dittrich P, et al. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res. 2010;24(3):445-450.20041430
Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs R D. 2006;7(3):163-172.16752942
Wu Y, Li S, Cui W, Zu X, Du J, Wang F. Ginkgo biloba extract improves coronary blood flow in healthy elderly adults: role of endothelium-dependent vasodilation. Phytomedicine. 2008;15(3):164-169.18258419
Xermelo (telotristat ethyl) [prescribing information]. Deerfield, IL: TerSera Therapeutics LLC; October 2020.
Xu AH, Chen HS, Sun BC, et al. Therapeutic mechanism of Ginkgo biloba exocarp polysaccharides on gastric cancer. World J Gastroenterol. 2003;9(11):2424-2427.14606069
Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-1092.24663230
Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R; GINDON Study Group. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. 2009;13(2):183-190.19347685
Ye B, Aponte M, Dai Y, et al. Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett. 2007;251(1):43-52.17194528
Yin O, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850.15608563
Yoshioka M, Ohnishi N, Koishi T, et al. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull. 2004;27(12):2006-2009.15577221
Zadoyan G, Rokitta D, Klement S, et al. Effect of Ginkgo biloba special extract EGb 761 on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol.2012;68(5):553-560.22189672
Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; May 2020.
Zeng X, Liu M, Yang Y, Li Y, Asplund K. Ginkgo biloba for acute ischaemic stroke. Cochrane Database Syst Rev. 2005;(4):CD003691.16235335
Zhang J, Yang S, Chen F, Li H, Chen B. Ginkgetin aglycone ameliorates LPS-induced acute kidney injury by activating SIRT1 via inhibiting the NF-κB signaling pathway. Cell Biosci. 2017;7:44.28852469
Zhang S, Zhuang J, Yue G, et al. Lipidomics to investigate the pharmacologic mechanisms of ginkgo folium in the hyperuricemic rat model. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:407-415.28672255
Zheng Y, Xie Y, Qi M, et al. Ginkgo biloba extract Is comparable with donepezil in improving functional recovery in Alzheimer's disease: results from a multilevel characterized study based on clinical features and resting-state functional magnetic resonance imaging. Front Pharmacol. 2021;12:721216. doi:10.3389/fphar.2021.72121634413779
Zuo XC, Zhang BK, Jia SJ, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol. 2010;66(5):503-509.20186406
Zurth C, Koskinen M, Fricke R, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747-759.31571146

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.